iodixanol (Visipaque)

dimeric contrast media; structure given in first source

Also Known As:

Visipaque; Visipaque Unique Softpac; contrast media 2-5410-3; iodixanol-320; 1,3-Benzenedicarboxamide, 5,5'-((2-hydroxy-1,3-propanediyl)bis(acetylimino))bis(N,N'-bis(2,3-dihydroxypropyl)-2,4,6-triiodo)-, (16alpha)-

Networked: 266 relevant articles (9 outcomes, 45 trials/studies)

Relationship Network

Drug Context: Research Results

Organic Chemicals: 133
- Hydrocarbons: 1713
  - Cyclic Hydrocarbons: 97
    - Aromatic Hydrocarbons: 291
      - Benzene Derivatives: 17
        Benzoates: 426
        Iodobenzoates
        Triiodobenzoic Acids: 2
        iodixanol: 266
- Carboxylic Acids: 973
  - Carbocyclic Acids
    - Benzoates: 426
      - Iodobenzoates
        Triiodobenzoic Acids: 2
        iodixanol: 266

Experts

1.	Jost, Gregor: 5 articles (12/2014 - 02/2009)
2.	Pietsch, Hubertus: 5 articles (12/2014 - 02/2009)
3.	Solomon, Richard: 5 articles (10/2014 - 06/2009)
4.	Aspelin, Peter: 4 articles (07/2012 - 02/2005)
5.	Chai, Chun-Ming: 4 articles (11/2010 - 08/2002)
6.	Ronco, Claudio: 3 articles (01/2020 - 01/2014)
7.	Bellomi, Massimo: 3 articles (03/2018 - 06/2006)
8.	Franklin, Tammy: 3 articles (10/2014 - 11/2012)
9.	Li, Lu-Ping: 3 articles (10/2014 - 11/2012)
10.	Prasad, Pottumarthi V: 3 articles (10/2014 - 11/2012)

Related Diseases

1.	Pain (Aches) 11/15/2014 - "Iso-osmolar contrast (iodixanol) reduces patient and operator pain during peripheral angiography." 05/24/2011 - "A greater reduction in the magnitude of pain was observed with IOCM (iodixanol), particularly with selective limb and carotid/intracerebral procedures. " 07/01/1997 - "Further, 4.1% in the iodixanol group experienced pain and/or severe heat sensation vs 19. " 10/01/2010 - "To determine prospectively the incidence and nature of immediate and delayed adverse drug reactions occurring after administration of iodixanol for contrast-enhanced computed tomography (CT) in routine practice in nonselected patients, and to assess patient comfort (pain and sensations of heat or coldness). " 09/01/1996 - "The results of this study support the conclusion that iodixanol at 320 mg I/kg is safe and effective for adult aortography and peripheral arteriography and causes significantly less injection-related pain than ioxaglate."
2.	Renal Insufficiency (Renal Failure) 07/01/2007 - "Our study was a retrospective evaluation comparing the incidence of contrast-induced nephropathy in consecutive patients with underlying renal insufficiency undergoing diagnostic CT examinations receiving iodixanol from November 2003 to June 2005 with a comparison group of patients with normal baseline renal function over the same period. " 11/01/2013 - "Using clinically healthy cattle and those with renal failure, the GFR values estimated from the Holstein equation were in good agreement with those by the multisample method using iodixanol (r=0.89, P=0.01). " 11/22/2012 - "Only one patient showed renal failure, one week after dosing with iodixanol. " 07/01/2007 - "In the group of patients receiving iodixanol with underlying renal insufficiency (189 patients), 9.0% developed contrast nephropathy (P = 0.015) with 4.8% of patients developing irreversible renal damage (P = 0.03). " 11/01/2006 - "Hospitals switching CM to iodixanol experienced a doubling in clinically significant renal failure after cardiac procedures. "
3.	Acute Coronary Syndrome 11/01/2002 - "In patients with an acute coronary syndrome, there was a trend toward a reduced incidence of the combined endpoint in the Hexabrix compared to the Visipaque group, although this did not reach statistical significance (17.2% vs. 24.8%; P = 0.17). " 01/01/2013 - "The aim of this study is to compare iodixanol and iopamidol in patients with acute coronary syndrome (ACS) who are currently undergoing coronary angiography. " 01/01/2013 - "[Nephrotoxicity of iodixanol versus iopamidol in patients with acute coronary syndrome]."
4.	Hypoxia (Hypoxemia) 11/01/2012 - "Additionally, iodixanol induced a dose-dependent increase in renal medullary hypoxia." 05/01/2012 - "Functional MR imaging of the kidneys demonstrates increased R2* in the inner medulla only after the administration of the iodixanol potentially indicating hypoxia and thus a pathomechanism of contrast-induced nephropathy." 01/01/2014 - "Compared with iodixanol, iohexol induced a significantly greater reduction in renal function, severe renal tissue damage, intrarenal hypoxia, and apoptotic tubular cells. " 07/01/2002 - "Iodixanol produced a more sustained medullary hypoxia than ioxaglate when injected selectively into the dog renal artery. " 07/01/2002 - "The hypoperfusion and hypoxia lasted significantly longer with iodixanol than with ioxaglate. "
5.	Infarction (Infarctions) 11/01/2000 - "Physiologic variables and infarct size were measured Pretreatment with iodixanol reduced infarct size significantly compared with control and thus afforded protection against ischemia. " 10/01/2014 - "T2WI mean infarct volumes were 242 ± 89, 324 ± 70, and 345 ± 92 mm(3) at 6 hours, and 341 ± 147,470 ± 91, and 462 ± 71 mm(3) at 24 hours in the iodixanol, iopamidol, and saline groups, respectively. " 02/01/2009 - "There was an excellent agreement of infarct sizes among NBT-, iopromide- and iodixanol-enhanced MDCT with concordance-correlation coefficients ranging from rho(c)=0.9928-0.9982. " 11/01/2015 - "Iso-osmolal iodixanol (290 mOsm/kg H2O) infusion demonstrated smaller infarcts and less intracranial hemorrhage compared with low-osmolal iopamidol and saline. " 10/01/2014 - "Intra-arterial infusion of nonionic iso-osmolar iodixanol showed reduced infarct volume and reduced cortical intracranial hemorrhage areas in comparison with nonionic low-osmolar iopamidol and saline. "

Related Drugs and Biologics

1.	Ioxaglic Acid (Ioxaglate Meglumine)
2.	iodixanol (Visipaque)
3.	iopromide (Ultravist)
4.	Iohexol (Omnipaque)
5.	Contrast Media
6.	Iopamidol (Isovue)
7.	Creatinine
8.	iotrolan (Isovist)
9.	Iodine
10.	iomeprol

Related Therapies and Procedures

1.	Percutaneous Coronary Intervention
2.	Nephrectomy
3.	Injections
4.	Intra-Arterial Injections
5.	Intravenous Administration